



December 20, 2016

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2012-003054-92/ Novartis Protocol ID CACZ885G2402

*An open-label, multi-arm, non-comparative safety and tolerability study of canakinumab (ACZ885) in patients with active Systemic Juvenile Idiopathic Arthritis (SJIA)*

Trial CACZ885G2402 was cancelled with no patient enrollment and as such, no results will be reported.